一个跨国调查潜在的参与者对眼部基因治疗的观点
Alexis Ceecee Britten-Jones1,2,3, Myra B McGuinness2,3,4, Fred K Chen2,3,5,6
1Department of Optometry and Vision Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
Gene therapy
|April 2, 2024
概括
大多数患有遗传性视网膜疾病 (IRD) 的患者愿意接受眼部基因疗法,但许多人缺乏足够的知识. 解决知识差距是明智决策和治疗采用的关键.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 是一个遗传学.
- 医学研究 医学研究
背景情况:
- 眼部基因疗法正在迅速发展.
- 了解患者的观点对于指导治疗选择和研究至关重要.
- 遗传性视网膜疾病 (IRD) 是基因疗法的首要目标.
研究的目的:
- 评估潜在的接受者与IRDs之间的眼部遗传疗法的知识,态度和看法.
- 确定患者信息来源,并在国际上比较观点.
- 为未来患者参与和临床采用策略提供信息.
主要方法:
- 来自35个国家的496名参与者 (IRD患者,护理人员) 的国际横截面调查.
- 使用的验证仪器:AGT-Eye,EQ-5D-5L,NEI-VFQ-25,PACT-22.2. 这些仪器都已被验证.
- 结果与之前的澳大利亚全国调查进行了比较.
主要成果:
- 90%的参与者可能会接受眼性基因疗法.
- 只有45%的人认为他们对基因疗法有很好的了解.
- 研究登记册和互联网是主要的信息来源.
- 美国受访者对结果的了解更高;澳大利亚受访者认为治疗价值更高.
结论:
- 在IRD患者中,眼部基因治疗存在显著的意愿.
- 关于结果和财务方面的知识差距仍然存在.
- 知情同意,共享决策和临床采用需要解决这些知识缺陷.
相关概念视频
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...


